Kenya Association of Pharmaceutical Industry (KAPI)

What Kenya Association of Pharmaceutical Industry (KAPI) does

KAPI - Industry Alliance of Health Products and Technologies is a non-profit membership association founded in the late 1960s and headquartered in Nairobi, Kenya. It represents biopharmaceutical manufacturers and their local representatives operating in Kenya, with a membership roster that spans global majors (Roche, Pfizer, MSD, AstraZeneca, J&J, Bayer, GSK, Novartis, Merck, Novo Nordisk, Boehringer Ingelheim, Servier, Reckitt, B. Braun, Haleon) alongside local manufacturers and distributors (Surgipharm, Beta Healthcare, Harleys, mydawa). KAPI is the recognized industry voice for the pharmaceutical and broader health products sector, engaging with the Pharmacy and Poisons Board (PPB), the Ministry of Health, WHO, and IFPMA on policy, regulatory, and ethics matters.

KAPI's service portfolio is built on four pillars: Policy and Advocacy, Market Intelligence, Thought Leadership, and Ethics and Business Integrity. Beyond these pillars, the association delivers discrete programs including pharmacovigilance training (QPPV Learning Summit), regulatory reliance guidance, serialization and track-and-trace advisory in partnership with GS1 Kenya and RAPSK, and the Professional Management Trainee Program (PGMT). It also produces publications such as the Universal Health Coverage Report and supports the Africa Medicines Agency rollout through task force participation. KAPI does not develop proprietary technology products; its technology footprint is limited to adoption of GS1 standards for traceability and digital channels (website, social media, Substack, YouTube) for stakeholder engagement.

KAPI's revenue is generated through annual membership subscription fees across three tiers - Full Members (R&D biopharmaceutical, medical devices, and diagnostics companies), Associate Members (pharmaceutical companies, distributors, and systems strengthening organizations), and Honorary Members (nominated distinguished individuals). Specific fee schedules are not publicly disclosed and prospective members are directed to the secretariat. Beyond membership fees, KAPI generates ancillary revenue through event registrations and training programs (e.g., the 50-50% co-funded QPPV Learning Summit). The secretariat is small at approximately 10 employees, including an Executive Director and Administrative Manager, and operations are run from a single headquarters office in Nairobi.

Name

Kenya Association of Pharmaceutical Industry (KAPI)

Legal name

Kenya Association of Pharmaceutical Industry (KAPI)

Website

https://kapikenya.org

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

1–10 employees

Short description

KAPI is a Kenyan non-profit membership association founded in the late 1960s that represents biopharmaceutical manufacturers and their local representatives. It delivers policy advocacy, regulatory engagement, ethics oversight, and pharmacovigilance training to its multinational and local pharma members.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association Services

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600), Services-Management Consulting Services (8742)

akta.pro primary industry

KOL Engagement & Medical Education (Advisory Boards/CME Support) (HLAGALAM)

Keywords

• Pharmaceutical industry association
• Policy advocacy services
• Regulatory affairs advisory
• Pharmacovigilance training
• Biopharmaceutical representation

Headquarters

HQ city

Nairobi

HQ country

Kenya

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Membership Fees: KAPI generates revenue through membership fees from Full Members (R&D based biopharmaceutical, medical devices & diagnostics companies), Associate Members (pharmaceutical companies, distributors and pharmaceutical systems strengthening companies), and Honorary Members (nominated distinguished individuals). The specific fee structure is not publicly disclosed.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

KAPI is a membership-based industry association representing biopharmaceutical manufacturers and their local representatives in Kenya. The organization delivers member services across four pillars: Policy and Advocacy, Market Intelligence, Thought Leadership, and Ethics and Business Integrity. Services include regulatory engagement, pharmacovigilance training, serialization/track-and-trace advisory, ethical business practice promotion under the KAPI Code of Practice, and capacity-building workshops.

Product overview

KAPI – Industry Alliance of Health Products and Technologies is a membership-based association established in the late 1960s representing biopharmaceutical manufacturers and their local representatives. The organization offers a portfolio of member services organized around four core pillars: Policy and Advocacy, Market Intelligence, Thought Leadership, and Ethics and Business Integrity. These services include pharmacovigilance training programs, regulatory reliance guidance, serialization and track-and-trace advisory, the Patient Safety 101 toolkit, and a Professional Management Trainee Program. KAPI also produces publications including reports on Universal Health Coverage and collaborates with partners on regulatory harmonization initiatives such as the Africa Medicines Agency and WHO Global Benchmarking Tool ML3.

Differentiator

Problem solved

Functional benefit

Products and services

• Policy and Advocacy Member service through which KAPI engages with regulators and government to inform policies that support an enabling business environment for the health and pharmaceutical industry. Includes working committees providing feedback on regulations and guidelines. Targeted at KAPI member companies (Full, Associate and Honorary Members).
• Market Intelligence Member service providing industry insights and updates shared through KAPI Committees on matters affecting the pharmaceutical and health products industry, including serialization, track and trace, healthcare financing, SHA engagements, and pharmacovigilance intelligence. For KAPI member companies.
• Thought Leadership Member service delivering professional and technical engagement through workshops, seminars, and working groups to shape policy, practice and healthcare trends in Kenya. For KAPI member companies and broader industry stakeholders.
• Ethics and Business Integrity Service anchored on the KAPI Code of Practice (2016) and IFPMA guidance that promotes ethical business conduct in the pharmaceutical industry, addressing promotion practices, transparency, anti-corruption, and engagement with healthcare professionals. For KAPI member companies and the broader industry.
• Pharmacovigilance Training Programs Pharmacovigilance capacity-building programs including the QPPV Learning Summit covering Qualified Person for Pharmacovigilance requirements, adverse event reporting, PSUR, PSMF, RMP, BCP preparation, and regulatory alignment. For pharmacovigilance professionals in member companies.
• Regulatory Reliance Guidance and Workshops Educational service providing guidance on regulatory reliance practices, helping industry professionals and regulators implement reliance pathways for regulatory decisions. Includes workshops, surveys, and collaboration with PPB to refine reliance guidelines. For pharmaceutical and medical technology industry professionals.
• Patient Safety 101 Toolkit Educational resource explaining adverse events and adverse drug reactions, patient reporting procedures, and the role of healthcare professionals, pharmaceutical companies, and health authorities in pharmacovigilance. For patients, healthcare professionals, and industry stakeholders.
• Serialization and Track-and-Trace Advisory Advisory and training service on pharmaceutical serialization and track-and-trace implementation using GS1 standards, helping members prepare for and comply with traceability requirements, including DataMatrix codes, unique product identifiers, and integration with national systems such as KENTRADE. For KAPI member companies and supply chain stakeholders.
• Professional Management Trainee Program (PGMT) Early-career graduate management trainee program offering hands-on exposure, mentorship, and practical experience in healthcare systems, policy, advocacy, and organizational management. For young professionals seeking careers in pharmaceutical and healthcare policy.
• Universal Health Coverage Report Industry publication on Universal Health Coverage addressing industry collaboration, government partnerships, and strengthening healthcare systems for UHC implementation in Kenya. For policy makers, industry stakeholders, and healthcare professionals.

Quantifiable outcome

• Over 150 participants in Regulatory Reliance Workshop (70+ in person, 150+ online)
• +2 more outcomes

Named customers19 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Partnerships

15 partnerships are on record, tiered core and minor.

• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)coreStrategic or Co-development PartnerKAPI is affiliated with IFPMA as its Kenya member association. IFPMA represents research-based pharmaceutical companies and associations worldwide. KAPI participates in IFPMA initiatives including the Africa Regulatory Network and contributes to global health policy discussions.
• Pharmacy and Poisons Board (PPB)coreStrategic or Co-development PartnerKAPI maintains close working relationships with PPB, Kenya's medicines regulatory authority. The partnership includes regulatory reliance discussions, guideline reviews, WHO GBT Maturity Level 3 evaluation, and industry-regulator engagement forums.
• Medical Technology Industry Association of Kenya (MEDAK)coreStrategic or Co-development PartnerKAPI collaborates with MEDAK on joint workshops including the Regulatory Reliance Workshop and Post-Approval Changes Workshop, bringing together pharmaceutical and medical device industry perspectives.
• Pharmaceutical Society of Kenya (PSK)minorStrategic or Co-development PartnerKAPI partners with PSK on industry events and healthcare professional engagement, including World Patient Safety Day activities.
• World Self-Medication Industry (WSMI)minorStrategic or Co-development PartnerKAPI maintains affiliation with WSMI for self-medication and consumer healthcare industry coordination.
• East African Business Council (EABC)minorStrategic or Co-development PartnerKAPI affiliates with EABC for East African regional business coordination and harmonization efforts.
• Kenya Employers Association (KEPSA)minorStrategic or Co-development PartnerKAPI affiliates with KEPSA for employer coordination and business policy engagement in Kenya.
• Kenya Healthcare Federation (KHF)minorStrategic or Co-development PartnerKAPI collaborates with KHF on healthcare industry coordination and policy advocacy.
• Regulatory Affairs Professionals Society of Kenya (RAPSK)minorStrategic or Co-development PartnerKAPI co-hosted the Introduction to Serialization, Track and Trace Webinar with RAPSK in June 2025.
• Egyptian Drug Authority (EDA)minorStrategic or Co-development PartnerEDA participated in KAPI's Regulatory Reliance Workshop as an international speaker, sharing experiences on achieving WHO Maturity Level 3 and regulatory reliance practices.
• WHO (World Health Organization)coreStrategic or Co-development PartnerKAPI supports WHO initiatives including the Malaria Vaccine Implementation Programme (MVIP) with RTS,S vaccine. KAPI also engages with WHO on regulatory system strengthening and Good Reliance Practices.
• Access Accelerated InitiativecoreStrategic or Co-development PartnerKAPI participates in the Access Accelerated initiative led by 22 biopharmaceutical companies to improve NCD prevention and care in low and lower-middle income countries. KAPI plays a leading role in the local rollout of this global initiative.
• Africa Medicines AgencycoreStrategic or Co-development PartnerKAPI serves as council member of the Africa Engagement Committee and member of the Africa Medicines Agency task force. Kenya has ratified and deposited instruments in support of AMA, with KAPI's advocacy contributing to this milestone.
• Pfizer (as IFPMA President representative)minorStrategic or Co-development PartnerIan Read, CEO of Pfizer and IFPMA President, led Access Accelerated initiative launch. KAPI coordinates with member companies on Access Accelerated implementation in Kenya.
• World Bank Group (through Access Accelerated)coreStrategic or Co-development PartnerWorld Bank Group partners with Access Accelerated to identify solutions for financing, regulatory and service delivery barriers at country level. KAPI engages with World Bank through this initiative and Health Emergency Preparedness, Response and Resilience Project supporting PPB recruitment.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/KapiKenya
• YouTubeyoutube.com/channel/UC1L8ISM0w15GmCUp_HYoMfQ
• Facebookfacebook.com/KenyanPharma
• LinkedInlinkedin.com/company/kenya-association-of-pharmaceutical-industry-kapi

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kenya Association of Pharmaceutical Industry (KAPI)